Compare AST SpaceMobile Inc (ASTS) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AST SpaceMobile Inc vs Incyte Corporation — how do they compare? AST SpaceMobile Inc trades at $71.86 (market cap $20.54B), while Incyte Corporation trades at $120.45 (market cap $24.65B). The key difference: Incyte Corporation is the larger of the two by market cap, and Incyte Corporation is trading nearer its 52-week high, AST SpaceMobile Inc nearer its low. Which is the better fit depends on your goals.
| ASTS | INCY | |
|---|---|---|
Market Cap | $20.54B | $24.65B |
Sector | Media | Health |
52-Week High | $133.09 | $129.93 |
52-Week Low | $36.91 | $79.19 |
Enterprise Value | $21.25B | $20.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AST SpaceMobile (ASTS) trades at $71.94, up 6.8% on the day, reflecting strong momentum despite recent earnings misses. The stock shows a bullish technical signal with key resistance at $73 and support at $69. Fundamentally, revenue grew to $71M in 2025, but net losses persist at -$342M, with a negative net margin of -482.17%. The company maintains a $1.3B backlog and raised its 2026 revenue guidance to $150M-$200M, indicating growth potential amid high cash burn.
Outlook: ASTS offers speculative upside driven by satellite network expansion and partnerships, with a consensus price target of $85.45 (19% upside). Risks include sustained losses, execution delays, and high valuation (P/S of 230.94). Investors should weigh growth prospects against financial sustainability concerns.
Incyte Corporation (INCY) trades at $120.56, up 1.84% on the day, near its 52-week high of $120.70. The stock shows a bullish technical trend with strong earnings beats in Q1 and Q2 2026, including Q2 EPS of $3.09 versus $2.15 expected. Revenue growth accelerated to $5.14 billion in 2025, with a net income margin of 27.71%. Recent news highlights EU approval for Opzelura and a raised 2026 revenue outlook, fueling positive momentum.
The outlook remains favorable with analyst consensus at Buy and a $122.82 price target, though risks include reliance on key drugs like Jakafi and competitive pressures. Earnings growth and pipeline advancements support upside, but investors should monitor execution against guidance and regulatory developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AST SpaceMobile Inc
AST SpaceMobile Inc is a satellite designer and manufacturer. The company is building the global cellular broadband network in space to operate directly with standard, unmodified mobile devices based on extensive IP and patent portfolio. AST is on a mission to eliminate the connectivity gaps faced by mobile subscribers and finally bring broadband to the billions who remain unconnected.
Read more on ASTS →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
